CNS Pharmaceuticals, Inc. (CNSP)

0.2150 +0.0060 (+2.87%) At close: 04:00PM EDT

CNS Pharmaceuticals, Inc.

2100 West Loop South
Suite 900
Houston, TX 77027
United States
800 946 9185
https://www.cnspharma.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 3

Key executives

Name	Title	Pay	Exercised	Year born
Mr. John Michael Climaco Esq., J.D.	CEO, President & Director	525k	N/A	1969
Mr. Christopher S. Downs CPA, CTP, FP&A	Chief Financial Officer	382.16k	N/A	1979
Dr. Sandra L. Silberman M.D., Ph.D.	Chief Medical Officer	261.2k	N/A	1956
Dr. Waldemar Priebe Ph.D.	Founder	N/A	N/A	N/A
Dr. Donald H. Picker Ph.D.	Chief Science Officer	N/A	N/A	1946

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc., Reata Pharmaceuticals, Inc., Pomeranian Medical University, and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. The company was incorporated in 2017 and is based in Houston, Texas.

Corporate governance

CNS Pharmaceuticals, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.